HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24

Leukemia Research

Volumn 30, Issue 8, 2006, Pages 1005-1011

  Ikezoe, Takayuki ^a   Bandobashi, Kentaro ^a   Yang, Yang ^a   Takeuchi, Seisho ^a   Sekiguchi, Nobuo ^b   Sakai, Shuichi ^b   Koeffler, H Phillip ^c   Taguchi, Hirokuni ^a  

^a KOCHI UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1,25 Dihydroxyvitamin D3; 25 Hydroxyvitamin D3 24 hydroxylase (CYP24); Differentiation; Myeloid leukemia; Ritonavir

Indexed keywords

1,24,25 TRIHYDROXYCOLECALCIFEROL; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CYTOCHROME P450; PROTEINASE INHIBITOR; RITONAVIR; VITAMIN D DERIVATIVE;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELLULAR DISTRIBUTION; DOWN REGULATION; DRUG EFFECT; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION;

ANTIGENS, CD14; CALCITRIOL; CELL DIFFERENTIATION; CELL PROLIFERATION; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HIV PROTEASE INHIBITORS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITONAVIR; STEROID HYDROXYLASES; STRUCTURE-ACTIVITY RELATIONSHIP; SUPEROXIDES; TRANSCRIPTION, GENETIC;

EID: 33744830869     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.12.008     Document Type: Article

References (28)

1. 3 receptors: gene regulation and genetic circuitry. FASEB J 2 (1988) 3043-3053
2. 3 on primary cultures of human prostatic cells. Cancer Res 54 (1994) 805-810
3. 3. Endocrinology 136 (1995) 20-26
4. Danielpour D., Kadomatsu K., Anzano M.A., Smith J.M., and Sporn M.B. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 54 (1994) 3413-3421
5. 3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 66 (1997) 413-425
6. 3 metabolites. Cancer Res 43 (1983) 4443-4447
7. Bower M., Colston K.W., Stein R.C., Hedley A., Gazet J.C., Ford H.T., et al. Topical calcipotriol treatment in advanced breast cancer. Lancet 337 (1991) 701-702
8. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 87 (1990) 3929-3932
9. 3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res 50 (1990) 6857-6864
10. Asou H., Koike M., Elstner E., Cambell M., Le J., Uskokovic M.R., et al. 19-Nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92 (1998) 2441-2449
11. Hisatake J., O'Kelly J., Uskokovic M.R., Tomoyasu S., and Koeffler H.P. Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 97 (2001) 2427-2433
12. Kumar R. Metabolism of 1,25-dihydroxyvitamin D3. Physiol Rev 64 (1984) 478-504
13. Christakos S., Raval-Pandya M., Wernyj R.P., and Yang W. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 316 (1996) 361-371
14. Kumar G.N., Rodrigues A.D., Buko A.M., and Denissen J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277 (1996) 423-431
15. Ikezoe T., Hisatake Y., Said J.W., Taguchi H., and Koeffler H.P. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP 3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 15 64 (2004) 7426-7431
16. Ishigai M., Asoh Y., and Kumaki K. Determination of 22-oxacalcitriol, a new analog of 1alpha,25-dihydroxyvitamin D3, in human serum by liquid chromatography-mass spectrometry. J Chromatogr B: Biomed Sci Appl 706 (1998) 261-267
17. Ikezoe T., Daar E.S., Hisatake J., Taguchi H., and Koeffler H.P. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 96 (2000) 3553-3559
18. Ikezoe T., Tanosaki S., Krug U., Liu B., Cohen P., Taguchi H., et al. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood 104 (2004) 237-242
19. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regulat 22 (1984) 27-55
20. Olson D.P., Scadden D.T., D'Aquila R.T., and De Pasquale M.P. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 16 (2002) 1743-1747
21. Muindi J.R., Young C.W., and Warrell Jr. R.P. Clinical pharmacology of all-trans retinoic acid. Leukemia 8 Suppl 3 (1994) S16-S21
22. Ozpolat B., Mehta K., Tari A.M., and Lopez-Berestein G. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol 70 (2002) 39-47
23. Dwivedi P.P., Hii C.S., Ferrante A., Tan J., Der C.J., Omdahl J.L., et al. Role of MAP kinases in the 1,25-dihydroxyvitamin D3-induced transactivation of the rat cytochrome P450C24 (CYP24) promoter. Specific functions for ERK1/ERK2 and ERK5. J Biol Chem 277 (2002) 29643-29653
24. Yasunami Y., Hara H., Iwamura T., Kataoka T., and Adachi T. C-jun N-terminal kinase modulates 1,25-dihydroxyvitamin D3-induced cytochrome P450 3A4 gene expression. Drug Metab Dispos 32 (2004) 685-688
25. Ikezoe T., Saito T., Bandobashi K., Yang Y., Koeffler H.P., and Taguchi H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther 3 (2004) 473-479
26. Wang X., Rao J., and Studzinski G.P. Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-induced differentiation of human leukemia HL60 cells. Exp Cell Res 258 (2000) 425-437
27. Ly L.H., Zhao X.Y., Holloway L., and Feldman D. Liarozole acts synergistically with 1alpha, 25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140 (1999) 2071-2076
28. Zhao J., Tan B.K., Marcelis S., Verstuyf A., and Bouillon R. Enhancement of antiproliferative activity of 1alpha,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific. J Steroid Biochem Mol Biol 57 (1996) 197-202